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Cystic ﬁbrosis (CF) is a disease, which is characterized by persistent bacterial
infections of lung, and elementary and nutrient deﬁciency. The aim of the study
is a measurement of biochemical antioxidant factors in blood (glutathione, glu-
tathione peroxidase, zinc, uric acid, homocysteine), and comparison with clini-
cal and genetic parameters. CF patients group includes 29 persons (mean age-
11.8 years old): female-13 (mean age-11.0), male-16 (mean age-12.6). Disease
severity was estimated as a frequency of pulmonary exacerbations during the last
6 months. All cases were tested for 21 mutations of CFTR (delF508, delI507,
del21kb, 394delTT, R334X, R347P, G542X, G551d, R553X, N1303K, 2143delT,
2184insA, 2113delA, 2118del4, 2141insA, delE672, 2176insC, 2183AA/G, 2183de-
lAA, 2184delA, W128R), and classiﬁed in accordingly with CFTR genotypes into
5 subgroups: delF508/delF508; delF508/−; delF508/mut; mut/mut; wt/wt. Following
comparisons were made between these subgroups for clinical and biochemical
parameters: (1) cross comparison between all 5 subgroups; (2) delF508/delF508 vs
others; (3) carriers of delF508 vs non-carriers. A signiﬁcant difference for frequency
of pulmonary exacerbations was identiﬁed between carriers of delF508 vs non-
carriers (2.8 and 1.5, resp.). Correlation analysis did not revealed links with any
of biochemical parameters, but the difference in average glutathione concentrations
in these groups (4.69 and 3.7, resp.) was noted. Disease severity in CF patients is
related with a kind of CFTR mutation, and delF508 is a marker of poorer clinical
course. Also, data suggest a potential role of glutathione for ameliorating of clinical
course in CF patients.
